Strategic Partnerships

Immuno-Biological Laboratories, Japan

Intellect granted IBL an exclusive world-wide license to sell certain antibodies for research and diagnostic purposes. Intellect acquired exclusive right to develop and commercialize certain antibodies for therapeutic applications.

MRCT

Intellect Medical Research Council Technology (MRCT) entered into an agreement under which MRCT agreed to apply its proprietary technology and advanced know-how to humanize Intellect's beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer's disease.

NYU Medical School and the University of South Alabama Research Foundation

Intellect is the exclusive licensee of patents relating to OX1 and OX2 for the treatment of Alzheimer’s and related diseases.

Undisclosed major pharmaceutical companies

Intellect has granted non-exclusive royalty-bearing licenses to its ANTISENILIN platform technology and IP concerning monoclonal antibodies for the treatment of Alzheimer’s disease to several major pharmaceutical companies. Further information concerning its license agreements can be seen in the company’s filings with the Securities and Exchange Commission.

Read More

ViroPharma Incorporated

Intellect has granted an exclusive License to ViroPharma Incorporated (Nasdaq: VPHM) regarding certain of Intellect's licensed patents and patent applications related to Intellect’s clinical stage drug candidate, OX1, a multimodal, metal-binding, extremely potent antioxidant molecule, which has been demonstrated to protect nerve cells from highly oxidizing neurotoxins. ViroPharma plans to develop and commercialize OX1 as a treatment of Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation. Under the terms of the Exclusive License Agreement, Intellect has agreed to transfer to ViroPharma all of Intellect’s intellectual property rights, data and know-how related to its OX1 research and development program. In return, ViroPharma has paid a $6.5 million up-front licensing fee and will pay additional milestones based upon defined events. The maximum of these milestone payments assuming successful advancement to market could amount to $120 million. In addition, ViroPharma will pay a tiered royalty of up to a maximum of low double digits based on annual net sales.